Weishi Li is a partner in the firm’s Shanghai office. Her practice covers a wide range of technology-related transactions across multiple sectors, including the life sciences and hi-tech industries. She has extensive experience assisting multinational companies and Chinese companies in structuring and negotiating cross-border transactions with a significant intellectual property element, such as technology joint ventures and strategic alliances. Ms. Li has particular expertise in the life sciences sector, having assisted many western and Chinese life sciences companies in structuring and negotiating commercial, corporate and partnering transactions in China, including strategic collaborations, joint ventures, licensing, acquisitions, co-promotion and distribution arrangements.
65
Following several years of drafting and public consultations, on April 13 the State Administration for Industry and Commerce of the People’s Republic of China (“SAIC”) released its Rules on the Prohibition of Abuses of Intellectual Property Rights for the Purposes of Eliminating or Restricting (...)
64
Earlier this month, China’s National Development and Reform Commission (“NDRC”) announced that it is conducting a wide-ranging probe into the costs and prices of pharmaceutical products sold by more than 60 multinational and domestic companies. NDRC has broad powers to enforce China’s Price (...)
